title: Evolution of neoadjuvant therapy for extended hepatic metastases--have we reached our (non-resectable) limit?
abstract: Surgical resection offers the best chance for cure in patients with colorectal liver metastases; however, only 15-25% of them can benefit from surgery. To increase resectability a number of strategies have been developed in different fields including chemotherapy, surgery, and radiology. Bringing them together into an integrated framework has expanded the number of patients that can be treated with curative intent. This review focuses on recent oncosurgical changes, their impact, and future directions.
authors.affiliation: AP-HP Hospital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France. rene.adam@pbr.aphp.fr
authors.forename: René
authors.initials: R
authors.lastname: Adam
authors.forename: Emir
authors.initials: E
authors.lastname: Hoti
authors.forename: Luis César
authors.initials: LC
authors.lastname: Bredt
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery* / Q000628:therapy; D020360:Neoadjuvant Therapy / Q000009:adverse effects; D009367:Neoplasm Staging; D012086:Reoperation
chemical_list: D000970:Antineoplastic Agents